Top

Published in:

01-12-2011 | Research

Dendritic cell generation and CD4⁺CD25^HIGHFOXP3⁺ regulatory T cells in human head and neck carcinoma during Radio-chemotherapy

Authors: PJ Schuler, V Börger, E Bölke, D Habermehl, C Matuschek, CA Wild, J Greve, M Bas, B Schilling, C Bergmann, S Trellakis, W Budach, T Gauler, S Brandau, S Lang, TL Whiteside, RV Sorg, TK Hoffmann

Published in: European Journal of Medical Research | Issue 2/2011

Abstract

Background

Regulatory T cells (Treg) and dendritic cells (DC) play an important role in tumor immunity and immune escape. However, their interplay and the effects of anti-cancer therapy on the human immune system are largely unknown.

Methods

For DC generation, CD14⁺ monocytes were enriched by immunomagnetic selection from peripheral blood of advanced head and neck squamous cell carcinoma (HNSCC) patients and differentiated into immature DC using GM-SCF and IL-4. DC maturation was induced by addition of TNFα. The frequency of CD4⁺CD25^highF0XP3⁺ Treg in HNSCC patients was analyzed before and after radio-chemotherapy (RCT) by four-color flow cytometry.

Results

In HNSCC patients, the frequency of Treg (0.33 ± 0.06%) was significantly (p = 0.001) increased compared to healthy controls (0.11 ± 0.02%), whereas RCT had variable effects on the Treg frequency inducing its increase in some patients and decrease in others. After six days in culture, monocytes of all patients had differentiated into immature DC. However, DC maturation indicated by CD83 up-regulation (70.7 ± 5.5%) was successful only in a subgroup of patients and correlated well with lower frequencies of peripheral blood Treg in those patients.

Conclusion

The frequency of regulatory T cells is elevated in HNSCC patients and may be modulated by RCT. Monocyte-derived DC in HNSCC patients show a maturation deficiency ex vivo. Those preliminary data may have an impact on multimodality clinical trials integrating cellular immune modulation in patients with advanced HNSCC.

Oddone N, Morgan GJ, Palme CE, et al.: Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict out-come and the need to improve survival. Cancer 2009, 115: 1883–1891. 10.1002/cncr.24208PubMedCrossRef

Nicolette CA, Healey D, Tcherepanova I, et al.: Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007,25(Suppl 2):B47-B60.PubMedCrossRef

O'Neill DW, Adams S, Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104: 2235–2246. 10.1182/blood-2003-12-4392PubMedCrossRef

Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004, 53: 240–248. 10.1007/s00262-003-0468-6PubMedCrossRef

Whiteside TL: Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets 2007, 7: 633–642. 10.2174/156800907782418310PubMedCrossRef

Hoffmann TK, Muller-Berghaus J, Ferris RL, et al.: Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002, 8: 1787–1793.PubMed

Sorg RV, Ozcan Z, Brefort T, et al.: Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003, 26: 374–383. 10.1097/00002371-200307000-00010PubMedCrossRef

Higano CS, Schellhammer PF, Small EJ, et al.: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115: 3670–3679. 10.1002/cncr.24429PubMedCrossRef

Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009, 123: 735–746. 10.1016/j.jaci.2009.02.030PubMedCrossRef

10.

Brown K, Wong W: Diagnostic value of regulatory T cells: a new facet of a much studied cell population. Transplantation 2008, 86: 1485–1491. 10.1097/TP.0b013e31818f3d2aPubMedCrossRef

11.

Vandenbark AA, Offner H: Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology 2008, 125: 1–13.PubMedCentralPubMedCrossRef

12.

Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer 2010, 127: 759–767.PubMed

13.

Ladoire S, Arnould L, Apetoh L, et al.: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumorinfiltrating foxp3⁺ regulatory T cells. Clin Cancer Res 2008, 14: 2413–2420. 10.1158/1078-0432.CCR-07-4491PubMedCrossRef

14.

Perez SA, Karamouzis MV, Skarlos DV, et al.: CD4⁺ CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 2007, 13: 2714–2721. 10.1158/1078-0432.CCR-06-2347PubMedCrossRef

15.

Ghiringhelli F, Menard C, Puig PE, et al.: Metronomic cyclophosphamide regimen selectively depletes CD4⁺ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56: 641–648. 10.1007/s00262-006-0225-8PubMedCrossRef

16.

Strauss L, Bergmann C, Gooding W, Johnson JT, White-side TL: The frequency and suppressor function of CD4⁺ CD25highFoxp3⁺ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13: 6301–6311. 10.1158/1078-0432.CCR-07-1403PubMedCrossRef

17.

Zhou LJ, Tedder TF: CD14⁺ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996, 93: 2588–2592. 10.1073/pnas.93.6.2588PubMedCentralPubMedCrossRef

18.

Rapp M, Ozcan Z, Steiger HJ, et al.: Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 2006, 105: 41–50. 10.3171/jns.2006.105.1.41PubMedCrossRef

19.

Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004, 10: 3755–3762. 10.1158/1078-0432.CCR-04-0054PubMedCrossRef

20.

Lechmann M, Berchtold S, Hauber J, Steinkasserer A: CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol 2002, 23: 273–275. 10.1016/S1471-4906(02)02214-7PubMedCrossRef

21.

Whiteside TL: Tricks tumors use to escape from immune control. Oral Oncol 2009, 45: e119-e123. 10.1016/j.oraloncology.2009.03.006PubMedCrossRef

22.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O: Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010, 11: 38. 10.1186/1471-2172-11-38PubMedCentralPubMedCrossRef

23.

Kleinewietfeld M, Starke M, Di Mitri D, et al.: CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 2009, 113: 827–836. 10.1182/blood-2008-04-150524PubMedCrossRef

24.

Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Cutting edge: human CD4⁺ CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004, 172: 4676–4680.PubMedCrossRef

25.

Gabrilovich DI, chen HL, Girgis KR, et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2: 1096–1103. 10.1038/nm1096-1096PubMedCrossRef

26.

Kissel K, Berber S, Nockher A, et al.: Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion 2006, 46: 818–827. 10.1111/j.1537-2995.2006.00802.xPubMedCrossRef

27.

Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F: Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008, 57: 1579–1587. 10.1007/s00262-008-0505-6PubMedCrossRef

28.

Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW: Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Med Hypotheses 2008, 71: 802–804. 10.1016/j.mehy.2008.06.022PubMedCrossRef

Title: Dendritic cell generation and CD4+CD25HIGHFOXP3+ regulatory T cells in human head and neck carcinoma during Radio-chemotherapy
Authors: PJ Schuler
V Börger
E Bölke
D Habermehl
C Matuschek
CA Wild
J Greve
M Bas
B Schilling
C Bergmann
S Trellakis
W Budach
T Gauler
S Brandau
S Lang
TL Whiteside
RV Sorg
TK Hoffmann
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 2/2011
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-2-57

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dendritic cell generation and CD4⁺CD25^HIGHFOXP3⁺ regulatory T cells in human head and neck carcinoma during Radio-chemotherapy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the Apolipoprotein A5 gene

Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients

Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone

Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)

Lung function in adult patients with cystic fibrosis after using the eFlow® rapid for one year

Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study